ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hidroklorid - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 in 5. 1 za razpoložljive podatke o različnih kombinacijah).

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

novartis europharm limited - canakinumab - cryopyrin-associated periodic syndromes; arthritis, juvenile rheumatoid; arthritis, gouty - interleukin inhibitorji, - redno vročina syndromesilaris je indicirano za zdravljenje naslednjih autoinflammatory redno vročina sindromov, pri odraslih, mladostnikih in otrocih, starih 2 leti in več:cryopyrin-associated periodic syndromesilaris je primerna za zdravljenje cryopyrin-associated periodic sindromov (caps), vključno z:muckle-sindrom wells (mws),novorojenčku-nastop multisystem vnetne bolezni (nomid) / kronične infantilne nevrološke, kožne, sklepni sindrom (cinca),hude oblike družinsko hladno autoinflammatory sindrom (fcas) / družinsko hladno urtikarija (fcu) predstavitev z znaki in simptomi, ki presegajo hladno-induced urticarial izpuščaj na koži,. tumor nekroze faktor receptor, povezanih redno sindrom (pasti)ilaris je primerna za zdravljenje tumor nekroze faktor (tnf), receptor, povezanih redno sindrom (pasti). hyperimmunoglobulin d sindrom (hids)/mevalonate kinaza pomanjkljivosti (mkd)ilaris je primerna za zdravljenje hyperimmunoglobulin d sindrom (hids)/mevalonate kinaza pomanjkljivosti (mkd). družinsko sredozemlju kuge (fmf)ilaris je primerna za zdravljenje družinsko sredozemlju kuge (fmf). ilaris je treba v kombinaciji z colchicine, če je primerno. ilaris je prikazano tudi za zdravljenje:še vedno je diseaseilaris je primerna za zdravljenje aktivnega še vedno je bolezen odraslih, vključno z nastopom še vedno je bolezen (aosd) in sistemsko mladoletnike idiopatsko artritis (sjia) pri bolnikih, starih 2 leti in več, ki so se odzvali neustrezno na prejšnje zdravljenje s nesteroidna protivnetna zdravila (nesteroidnih protivnetnih zdravil) in sistemski kortikosteroidi. ilaris lahko podana kot monotherapy ali v kombinaciji z metotreksatom. uričnim arthritisilaris je primerna za simptomatsko zdravljenje odraslih bolnikov s pogostimi uričnega artritisa napadov (vsaj za 3 napade v zadnjih 12 mesecih) pri katerih nesteroidna protivnetna zdravila (nesteroidnih protivnetnih zdravil) in colchicine so kontraindicirana, se ne prenaša ali ne zagotavlja ustreznega odgovora, in v kateri je ponovil tečaji kortikosteroidi niso primerne.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

novartis europharm limited - travoprost - ocular hypertension; glaucoma, open-angle - ophthalmologicals, antiglaucoma preparations and miotics - zmanjšanje zvišanega očesnega tlaka pri odraslih bolnikih z očesno hipertenzijo ali glavkomom odprtega zakotja (glejte poglavje 5. znižanje zvišanega očesnega tlaka pri pediatričnih bolnikih, starih od 3 let < 18 let, s očesni hipertenzijo ali glavkom pediatričnih.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

novartis europharm limited - ruksolitinib (kot fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastična sredstva - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi je indiciran za zdravljenje odraslih bolnikov z polycythaemia vera, ki so odporne ali nestrpne hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, tip 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 in 5. 1 za razpoložljive podatke o različnih kombinacijah).

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - oftalmologi - zdravilo lucentis je navedeno v odraslih za:zdravljenje neovascular (mokro) starostna degeneracija rumene pege (amd)zdravljenje vida zaradi choroidal neovascularisation (cnv)zdravljenje vida zaradi diabetično degeneracija edem (dme)zdravljenje vida zaradi degeneracija edem sekundarnega do mrežnice vene (veja rvo ali centralne rvo).

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - odpoved srca - sredstva, ki delujejo na sistem renin-angiotenzin - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromid - pljučna bolezen, kronična obstruktivna bolezen - zdravila za obstruktivne pljučne bolezni, - zdravilo seebri breezhaler je indicirano za zdravljenje bronhodilatatorjev za vzdrževanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (kopb).

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformin hidroklorid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocitopenična, idiopatska - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 in 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 in 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.